“It is fantastic news that our patent covering our solvent and tackifier free polyurea adhesive which is being exploited in our transdermal delivery of testosterone for women has been granted in the US,” commented Pro
10th April 2024
Medherant’s testosterone TEPI Patch has been well-tolerated and has demonstrated excellent wearability.
General News
25th March 2024
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an a
General News